Pembrolizumab – Immunotherapy treatment
Medical professionals are continually investigating new ways to help mesothelioma patients. There are always a number of different trials looking at improving symptoms and curing mesothelioma. All of these trials can be found by looking on the NHS website. One such treatment currently on offer is private immunotherapy treatment.
The treatment is with a drug called Pembrolizumab. Pembrolizumab has not yet been approved by the National Institute for Health Care and Excellence (“NICE”) in the treatment of mesothelioma patients and therefore currently is not available as a free treatment on the NHS. We are unaware of any indication that NICE will be approving Pembrolizumab any time soon.
Pembrolizumab has, however, in limited clinical trials, demonstrated increased survival rates in mesothelioma patients. It is therefore something that many patients with mesothelioma are considering.
How does immunotherapy treatment work?
Put simply, the drug works by making the cancer highly visible to the patient’s own immune system. The patient’s own immune system then kills the cancer.
Immunotherapy treatment and mesothelioma claims
As Pembrolizumab is not currently approved by NICE as a treatment for patients with mesothelioma and is therefore not available on the NHS, the current cost of treatment on a private basis is estimated at £75,000.
Last year, at Boyes Turner, we were delighted to report our mesothelioma team’s success in securing a settlement for a client which included the cost of this treatment as a separate aspect of his claim. We insisted that as our medical expert believed our client should receive this treatment, he should not have to use the compensation he was awarded for other areas of his loss if he needed the immunotherapy treatment in the future.
Fortunately, our client did not have to go through court proceedings to achieve his settlement, but we were delighted to hear that in a recent mesothelioma claim, the court has now ordered that treatment for immunotherapy should be funded by the defendant’s insurers.
Instead of waiting for the treating doctors to advise that the mesothelioma sufferer could have immunotherapy treatment, the court in an attempt to reach a quick settlement for the injured claimant, ordered that he could at any time request the costs of his immunotherapy treatment be funded by the insurers.
An order was given for periodical payments, so that mesothelioma claims can be settled without the injured claimant having to wait until their condition deteriorates to the point that their need for immunotherapy treatment is confirmed. The claimant can have the peace of mind of knowing that if or when they need immunotherapy treatment, the insurers have agreed to fund it automatically, whatever the cost.
At Boyes Turner we work hard to ensure that as many of our mesothelioma-affected clients as possible receive lifetime settlements, and we welcome the good news that we do not have to delay the outcome of any mesothelioma claims pending the decision on eligibility for immunotherapy treatment.
Having successfully recovered the cost of immunotherapy treatment for our own eligible mesothelioma-affected clients, we will continue to push the boundaries to improve compensation in mesothelioma claims.
Our asbestos team are committed to helping change the futures of mesothelioma patients by continuing to research the disease and striving to improve management of symptoms.
Charities such as Mesothelioma UK are strong advocates of ongoing trials and improvements on symptom management for mesothelioma patients and the Boyes Turner asbestos claims team support their efforts with annual sponsorship and fundraising.
With a number of different trials now available for mesothelioma patients, this decision gives hope that settlement can still be reached in mesothelioma claims without eliminating the opportunity for a client to recoup their costs of any future experimental treatment.
Go to original information: lexology